{
  "ticker": "JNJ",
  "target_date": "2025-05-20",
  "actual_date": "2025-05-20",
  "collected_at": "2025-12-08T11:47:11.842560",
  "price": {
    "open": 148.99,
    "high": 150.66,
    "low": 148.78,
    "close": 150.28952026367188,
    "volume": 7351500,
    "change_1d_pct": 0.77,
    "change_7d_pct": -0.36,
    "change_30d_pct": 2.02
  },
  "technicals": {
    "rsi_14": 44.95,
    "sma_20": 150.41,
    "sma_50": 153.23,
    "macd": -1.363,
    "macd_signal": -1.339,
    "macd_histogram": -0.024,
    "bb_upper": 155.92,
    "bb_lower": 144.9,
    "price_vs_sma20_pct": -0.08,
    "price_vs_sma50_pct": -1.92,
    "volume_ratio": 0.91
  },
  "fundamentals": {
    "market_cap": 489159196672,
    "pe_ratio": 19.59749,
    "forward_pe": 19.153772,
    "price_to_book": 6.1623216,
    "price_to_sales": 5.3083506,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.3,
    "pct_from_52w_low": 44.32
  },
  "macro": {
    "spy": {
      "price": 589.47,
      "change_1d_pct": -0.34,
      "change_7d_pct": 1.69
    },
    "vix": {
      "level": 18.09,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.48
    },
    "dollar_index": {
      "level": 100.12
    },
    "gold": {
      "price": 3280.3
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma",
      "source": "Yahoo",
      "datetime": 1747779660,
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk",
      "url": "https://finnhub.io/api/news?id=c10d3e935f1da769afe8a3b36ecf11a8d40b61fa4022a0abe4b2353c8419d36b"
    },
    {
      "headline": "Tracking Tweedy Browne Portfolio - Q1 2025 Update",
      "source": "SeekingAlpha",
      "datetime": 1747771331,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b56a1197ba3557ed11605f018678b006950461bd3eaab99f2f9c8e953eefbdb4"
    },
    {
      "headline": "J&J Says FDA Advisory Panel Favors Benefit-Risk Profile of Darzalex Faspro in Myeloma Treatment",
      "source": "MarketWatch",
      "datetime": 1747766820,
      "summary": "J&J Says FDA Advisory Panel Favors Benefit-Risk Profile of Darzalex Faspro in Myeloma Treatment",
      "url": "https://finnhub.io/api/news?id=73e8398f321ff127b9afd3cb532b8f702c784e51f153a98550298bb317a3c41c"
    },
    {
      "headline": "Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference",
      "source": "SeekingAlpha",
      "datetime": 1747753855,
      "summary": "Johnson &amp; Johnson (NYSE:JNJ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ETCorporate ParticipantsJoe Wolk - EVP, Chief...",
      "url": "https://finnhub.io/api/news?id=74bf315e087a1a7e595c1e798036a55ca2777247c2180cf6c5e8d2c5ac9f4553"
    },
    {
      "headline": "Transcript : Johnson & Johnson Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 01",
      "source": "Finnhub",
      "datetime": 1747751723,
      "summary": "Presenter SpeechShagun Singh Chadha Hello, everyone. I am Shagun Singh, Senior Research Analyst at RBC. And I'm very happy to host the next session with Johnson & Johnson. Joining us from the",
      "url": "https://finnhub.io/api/news?id=124f6229ae3e21f9876803f4b8347b9a66650f5ade72680ee59987d33c7b4663"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    },
    {
      "form": "8-K",
      "date": "2025-04-30",
      "description": "jnj-20250424.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000141/jnj-20250424.htm"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877468.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000138/xslF345X05/wk-form4_1745877468.xml"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877247.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000135/xslF345X05/wk-form4_1745877247.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}